Concurrent Radiotherapy, Paclitaxel and Dose Escalating Carboplatin in the Treatment of Cervical Cancer - A Phase I Study

Background: Concurrent radiation therapy (RT) and chemotherapy represents the standard treatment of locally advanced cervical cancer. This study was designed to determined the feasibility and toxicity of concomitant administration of RT with twice per week paclitaxel and carboplatin. Materials and Methods: Nine women with cervical cancer stage IB2-IVA were treated with standard RT and twice per week paclitaxel at a dose of 30 mg/m(2) with carboplatin in escalating doses starting at an AUC of 5. Results: One out of the four patients who received carboplatin at AUC 5 developed grade III toxicity according to the National Cancer Institute (NCI) garding system. Two out of the five patients who received carboplatin at AUC 6 developed grade III toxicity. A clinical response was achieved in 8 patients (89%), with a complete response (CR) in 5 patients (56%). Conclusion: Combining RT with twice weekly paclitaxel (30 mg/m(2)) and carboplatin (AUC of 6) is a tolerated regimen, active in controlling locally advanced cervical cancer.